🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Looking forward to JPM25 and time with these bioluminaries.

Ready, set, degrade! So proud to share our work in Journal of Clinical Investigation, establishing a versatile approach for creating transgenic dTAG mice to degrade oncoproteins. We showcase that KRAS G12V degradation triggers antitumor immunity in lung cancer. Link: jci.org/articles/view/… 🧵

Elegant use of dTAG to characterize the immediate consequences of ZFN143 loss on transcriptional targets.

Terrific discussion of core strategy, bleeding edge technology and ideal partnerships with Christoph Westphal and Stanford Medicine Dean Lloyd Minor Longwood Fund JPM25.

Metastatic colorectal cancer is a difficult illness and targeted therapy has been elusive. Today brings new hope. Read about today’s landmark @US_FDAapproval for patients with previously treated KRAS G12C-mutated disease👇#MyCompany

RIP Downyflake. Have so many happy donut memories together.

Another terrific outcome for a NIBR-born medicine. Congratulations to Rene Hersperger, Christian Bruns and all who worked to develop this gorgeous little electrophile.

Wonderful to be among the The Mark Foundation for Cancer Research leadership and community in NYC, taking vital signs and exchanging perspectives on progress in cancer therapy.

These results show exciting clinical benefit & represent an important advance in #SCLC care for people in desperate need of more effective treatment options. Looking forward to sharing these findings with the scientific community as we strive to bring Amgen 🧪🔬🧬’s immunotherapy to

Can you get too much of a good thing? Turns out ovarian cancer cells recurrently delete BRD4 regulatory elements to mute expression. So cool, even better from close friends. cell.com/cell-genomics/…

Tumor infiltrating clonal hematopoiesis associated with poor outcomes in solid tumors. Wonder if this is how IL1B inhibition seemed to improve survival from cancer in CANTOS… nejm.org/doi/full/10.10…

This #DNADay, we’re celebrating DNA as a tool for innovation. Our DEL platform uses DNA barcoding to screen billions of molecules in parallel, accelerating discovery of small-molecule therapies targeting even the most elusive biology. #MyCompany

New in Nature Metabolism: CNS GIPR and GLP-1R are both essential for weight loss response to a GIPR-Ab/GLP-1 peptide–antibody conjugate in mice—and this signaling happens through brain regions that reach outside the blood–brain barrier. This provides a new perspective on central

At the Milken Institute Global Conference panel, we discussed how AI, genetics & protein engineering are transforming drug discovery. From our research targeting Lp(a) to uncovering potentially protective mutations in obesity, we’re entering a new era of precision and

Delighted to see LLF580 (efimosfermin alfa) acquired by GSK, an FGF21 biologic for MASH. Thanks to Boston Pharma for believing in this idea. Third NIBR-born spin-out to be acquired for approx $1 bn or more. endpts.com/gsk-to-pay-1-2…

Grateful to join the Strategic Vision in Drug Discovery panel at #SDDS2025. At Amgen, we’re decoding disease at atomic resolution—advancing precision-based solutions grounded in deep human biology. Honored to share ideas with leaders pushing the boundaries of science.

Hope you are having a restful and reflective Memorial Day weekend.

A new Nature Medicine study sheds light on why KRAS G12C–mutated NSCLC patients respond differently to treatment. Insights from two trials reveal molecular features and early blood-based markers that may predict outcomes. Grateful to our Amgen 🧪🔬🧬 team involved. #MyCompany

Amazing trip back home to Chicago for #ASCO2025, with our deeply dedicated Amgen oncology colleagues and our fearless leader Dr. soria. Feeling very hopeful about the future of cancer care, our industry continues to rise to the generational challenge.

Big news today: Phase 3 trial results published in NEJM highlight Amgen 🧪🔬🧬 innovation in small cell lung cancer (#SCLC). 🔗Read how #MyCompany is reshaping treatment options: bit.ly/3FsZ0SV